An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

NCT03801278 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Recurrent Bladder Cancer

Interventions

DRUG: FPA144

Sponsor

Five Prime Therapeutics, Inc.